Literature DB >> 15316797

Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.

Jurgen Lemiere1, Marleen Decruyenaere, Gery Evers-Kiebooms, Erik Vandenbussche, Rene Dom.   

Abstract

OBJECTIVE: Objective information about the onset and progression of cognitive impairment in Huntington's disease (HD) is very important in the light of appropriate outcome measures when conducting clinical trials. Therefore, we evaluated the progression of cognitive functions in HD patients and asymptomatic carriers of the HD mutation (AC) over a 2.5-year period. We also sought to detect the earliest markers of cognitive impairment in AC.
METHODS: A prospective study comparing HD patients, clinically asymptomatic HD mutation-carriers (AC) and non-carriers (NC). These groups were examined three times during a period of 2.5 years. At baseline the study sample consisted of 49 subjects. Forty-two subjects (19 HD patients, 12 AC and 11 NC) completed three assessments. A battery of neuropsychological tests measuring intelligence, attention, memory, language, visuospatial perception, and executive functions was performed.
RESULTS: The performance of HD patients deteriorated on the following cognitive tests: Symbol Digit Modalities Test (SDMT), Stroop Colour and Word, Boston Naming Test (BNT), Object and Space Perception and Trail Making Test-B. Longitudinal comparison of AC and NC revealed that performances on SDMT, Block Span, Digit Span Backwards, Hopkins Verbal Learning Test (learning and delayed recall) and Conditional Associative Learning Test are impaired in AC.
CONCLUSIONS: Tasks measuring mainly attention, object and space perception and executive functions adequately assess the progression of HD disease. Other cognitive functions do not significantly deteriorate. Furthermore, problems in attention, working memory, verbal learning, verbal long-term memory and learning of random associations are the earliest cognitive manifestations in AC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316797     DOI: 10.1007/s00415-004-0461-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  50 in total

1.  Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study.

Authors:  Marie-Noëlle W Witjes-Ané; Maria Vegter-van der Vlis; Jeroen P P van Vugt; Jan B K Lanser; Jo Hermans; Aeilko H Zwinderman; Gert-Jan B van Ommen; Raymund A C Roos
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

2.  Retest effects and cognitive decline in longitudinal follow-up of patients with early HD.

Authors:  A C Bachoud-Lévi; P Maison; P Bartolomeo; M F Boissé; G Dalla Barba; A M Ergis; S Baudic; J D Degos; P Cesaro; M Peschanski
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

3.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation.

Authors:  J R Campodonico; A M Codori; J Brandt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

4.  Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers.

Authors:  V Hahn-Barma; B Deweer; A Dürr; C Dodé; J Feingold; B Pillon; Y Agid; A Brice; B Dubois
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

5.  Variability in cognitive function among persons at high genetic risk of Huntington's disease.

Authors:  A J Lundervold; I Reinvang
Journal:  Acta Neurol Scand       Date:  1995-06       Impact factor: 3.209

Review 6.  Anatomic and behavioral aspects of frontal-subcortical circuits.

Authors:  J L Cummings
Journal:  Ann N Y Acad Sci       Date:  1995-12-15       Impact factor: 5.691

7.  Neuropsychological characteristics of Huntington's disease carriers: a double blind study.

Authors:  N K Rosenberg; S A Sørensen; A L Christensen
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

8.  Development of neuropsychological deficits in Huntington's disease.

Authors:  R C Josiassen; L M Curry; E L Mancall
Journal:  Arch Neurol       Date:  1983-12

Review 9.  Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD).

Authors:  N Quinn; R Brown; D Craufurd; S Goldman; J Hodges; K Kieburtz; O Lindvall; J MacMillan; R Roos
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

10.  Evidence for specific cognitive deficits in preclinical Huntington's disease.

Authors:  A D Lawrence; J R Hodges; A E Rosser; A Kershaw; C ffrench-Constant; D C Rubinsztein; T W Robbins; B J Sahakian
Journal:  Brain       Date:  1998-07       Impact factor: 13.501

View more
  68 in total

1.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

2.  Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice.

Authors:  Danielle A Simmons; Christopher S Rex; Linda Palmer; Vijay Pandyarajan; Vadim Fedulov; Christine M Gall; Gary Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-05       Impact factor: 11.205

3.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

4.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

5.  Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.

Authors:  Verónica Brito; Albert Giralt; Lilian Enriquez-Barreto; Mar Puigdellívol; Nuria Suelves; Alfonsa Zamora-Moratalla; Jesús J Ballesteros; Eduardo D Martín; Nuria Dominguez-Iturza; Miguel Morales; Jordi Alberch; Sílvia Ginés
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

6.  Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease.

Authors:  Kathryn V Papp; Peter J Snyder; James A Mills; Kevin Duff; Holly J Westervelt; Jeffrey D Long; Spencer Lourens; Jane S Paulsen
Journal:  Arch Clin Neuropsychol       Date:  2012-12-16       Impact factor: 2.813

7.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

8.  Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status.

Authors:  Leigh J Beglinger; Kevin Duff; Jessica Allison; Danielle Theriault; Justin J F O'Rourke; Anne Leserman; Jane S Paulsen
Journal:  J Clin Exp Neuropsychol       Date:  2009-10-29       Impact factor: 2.475

9.  Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease.

Authors:  Andrea C Solomon; Julie C Stout; Marjorie Weaver; Sarah Queller; Allison Tomusk; Kathryn Burr Whitlock; Siu L Hui; Jeanine Marshall; Jacqueline Gray Jackson; Eric R Siemers; Xabier Beristain; Joanne Wojcieszek; Tatiana Foroud
Journal:  Mov Disord       Date:  2008-10-15       Impact factor: 10.338

Review 10.  Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.

Authors:  S Klöppel; S M Henley; N Z Hobbs; R C Wolf; J Kassubek; S J Tabrizi; R S J Frackowiak
Journal:  Neuroscience       Date:  2009-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.